0 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Gastrointestinal by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 3178 ongoing clinical trials involving Gastrointestinal
Of the 3178 trials,1272 trials are in Phase II
Furthermore, 721 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Gastrointestinal by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Gastrointestinal. The largest number of ongoing clinical trials for Gastrointestinal is conducted in Asia-Pacific. Europe and North America are among other prominent regions engaged in Gastrointestinal-related drug trials.

Takeda Pharmaceutical Co Ltd: The leading ongoing Gastrointestinal related clinical trial sponsor

Takeda Pharmaceutical Co Ltd, is the top sponsor for Gastrointestinal-related ongoing clinical trials.

Institute of Liver and Biliary Sciences , Johnson & Johnson, Mayo Clinic, AbbVie Inc, and Pfizer Inc are among other notable clinical trial sponsors involved in Gastrointestinal. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Gastrointestinal

Adalimumab (Humira), Pembrolizumab (Keytruda), and Lenalidomide (Revlimid) are among the key marketed drugs involving Gastrointestinal.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as injection for subcutaneous route of administration. Humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab was first approved in 2002 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including AbbVie Inc.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Pembrolizumab is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Merck Sharp & Dohme Corp.

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Visit Report Store